<DOC>
	<DOCNO>NCT02991911</DOCNO>
	<brief_summary>The purpose study assess safety tolerability , describe dose-limiting toxicity ( DLTs ) , determine maximum tolerate dose ( MTD ) maximum administer dose ( MAD [ absence establish MTD ] ) single agent MEDI3726 subject mCRPC receive prior treatment abiraterone enzalutamide , without prior taxane-based chemotherapy mCRPC setting .</brief_summary>
	<brief_title>A Phase 1/1b Study MEDI3726 Adults Subjects With Metastatic Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age â‰¥ 18 year time screen . Histologically confirm diagnosis metastatic castrationresistant prostate adenocarcinoma ( mCRPC ) . Documented PD subject mCRPC assess Investigator define least one follow accord PCWG3 criterion : 1 . Radiographic progression . 2 . PSA progression . Prior exposure abiraterone enzalutamide least 12 week mCRPC set . NOTE : Subjects receive abiraterone enzalutamide mCRPC set eligible . In dose escalation : Prior taxanebased chemotherapy mCRPC setting : 1 . Required Arm A . 2 . Excluded Arm B . 3 . Optional Arm C. Subjects neuroendocrine , neuroendocrine differentiation and/or small cell prostate cancer . The subject receive conventional investigational anticancer treatment within 21 day first dose investigational product , follow modification : 1 . At least 14 day first dose investigational product since completion treatment abiraterone enzalutamide 2 . At least 14 day first dose investigational product since completion prior taxanebased chemotherapy 3 . At least 28 day first dose investigational product since completion treatment Radium223 . 4 . At least 42 day first dose investigational product since completion prior bicalutamide nilutamide treatment . NOTE : An LHRH agonist antagonist require ongoing testosterone suppression permit Inclusion Criterion satisfy . Prior exposure PSMAdirected therapy . Subjects previous radiotherapy treatment unresectable , locally advanced metastatic prostate cancer exclude : 1 . More 25 % marrowbearing bone irradiate . 2 . The last fraction radiotherapy administer within approximately 2 week prior first dose investigational product . Brain metastasis untreated , symptomatic , require therapy control symptom ; radiation , surgery , therapy control symptom brain metastasis within 2 month prior first dose investigational product .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metastatic , prostate cancer</keyword>
</DOC>